One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid a...

by Leslie R. Harrold, Heather J. Litman, Katherine C. Saunders, Kimberly J. Dandreo, Bernice Gershenson, Jeffrey D. Greenberg, Robert Low, Jeffrey Stark, Robert Suruki, Srihari Jaganathan, Joel M. Kremer, Mohamed Yassine
Published 2018-01-01